Andy Chevigné and his team, RTI-5152-12 is postulated to boost the amounts of opioid peptides that bind to classical opioid receptors in the Mind, resulting in heightened painkilling action. The LIH-RTI research groups proven a collaboration settlement and filed a joint patent application